We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$116M
(+3.2%)
Cap. Flow
-$18.8M
Cap. Flow
% of AUM
-0.51%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
146
New
53
Increased
24
Reduced
24
Closed
34
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$134M |
| 2 |
Eli Lilly
LLY
|
+$114M |
| 3 |
HOLX
Hologic
HOLX
|
+$80.8M |
| 4 |
NeoGenomics
NEO
|
+$60.6M |
| 5 |
Biogen
BIIB
|
+$55.7M |
Top Sells
| 1 |
AstraZeneca
AZN
|
+$182M |
| 2 |
Intuitive Surgical
ISRG
|
+$103M |
| 3 |
AbbVie
ABBV
|
+$66.8M |
| 4 |
Medtronic
MDT
|
+$61.4M |
| 5 |
Bausch Health
BHC
|
+$60M |
Sector Composition
| 1 | Healthcare | 95.4% |
| 2 | Technology | 1.61% |
| 3 | Financials | 0.67% |
| 4 | Consumer Discretionary | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$121B
| $192M | 5.18% |
950,000
+639,100
| +206% | +$134M |
|
|
2
AbbVie
ABBV
$431B
| $167M | 4.52% |
1,484,400
-592,800
| -29% | -$66.8M |
|
3
Arvinas
ARVN
$534M
| $143M | 3.86% |
1,854,000
+93,700
| +5% | +$6.5M |
|
|
4
Eli Lilly
LLY
$1.03T
| $130M | 3.51% |
+565,500
| New | +$114M |
|
5
Maravai LifeSciences
MRVI
$1.04B
| $124M | 3.34% |
2,963,545
+202,000
| +7% | +$7.83M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $122M | 3.29% |
753,000
+277,300
| +58% | +$44.5M |
|
7
Zentalis Pharmaceuticals
ZNTL
$340M
| $115M | 3.11% |
2,160,000
+896,700
| +71% | +$48M |
|
8
Avantor
AVTR
$7.65B
| $113M | 3.05% |
3,180,000
-1,805,100
| -36% | -$58.4M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $101M | 2.73% |
640,000
+62,100
| +11% | +$9.23M |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $85.7M | 2.32% |
882,500
-167,300
| -16% | -$13.6M |
|
|
HOLX
11
DELISTED
Hologic
HOLX
| $80.7M | 2.18% |
+1,208,800
| New | +$80.8M |
|
12
Syndax Pharmaceuticals
SNDX
$2.08B
| $79.2M | 2.14% |
4,615,000
+769,000
| +20% | +$14.1M |
|
|
EPIX
13
DELISTED
ESSA Pharma
EPIX
| $78.6M | 2.12% |
2,750,000
-90,000
| -3% | -$2.62M |
|
|
EXAS
14
DELISTED
Exact Sciences
EXAS
| $73.3M | 1.98% |
590,000
-8,000
| -1% | -$955K |
|
|
15
Medtronic
MDT
$103B
| $66.4M | 1.79% |
535,000
-489,200
| -48% | -$61.4M |
|
16
Neurocrine Biosciences
NBIX
$17.3B
| $66.3M | 1.79% |
681,000
+159,600
| +31% | +$15.3M |
|
17
Nuvation Bio
NUVB
$2.05B
| $64.9M | 1.75% |
6,966,376
-555,565
| -7% | -$6.34M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $64.3M | 1.74% |
943,000
+44,450
| +5% | +$2.9M |
|
|
19
Biogen
BIIB
$29.1B
| $63.7M | 1.72% |
+183,900
| New | +$55.7M |
|
|
20
NeoGenomics
NEO
$1.89B
| $61.7M | 1.67% |
+1,367,000
| New | +$60.6M |
|
21
Intellia Therapeutics
NTLA
$1.82B
| $61.5M | 1.66% |
+380,000
| New | +$29.6M |
|
|
NBP
22
NovaBridge Biosciences American Depositary Shares
NBP
$214M
| $61.2M | 1.65% |
729,000
-600,000
| -45% | -$39.6M |
|
|
CTLT
23
DELISTED
CATALENT, INC.
CTLT
| $58.4M | 1.58% |
540,000
-20,000
| -4% | -$2.14M |
|
24
Shattuck Labs
STTK
$647M
| $56.2M | 1.52% |
1,940,200
+609,815
| +46% | +$17.8M |
|
25
Centene
CNC
$32.9B
| $54.8M | 1.48% |
+751,200
| New | +$51.5M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH